Nancy Stagliano, Neuron23 CEO

Chas­ing Bris­tol My­ers and Bio­gen/De­nali, CNS biotech rais­es $100M in dash to­ward clin­ic

In the months af­ter South San Fran­cis­co-based Neu­ron23 an­nounced a com­bined Se­ries A and Se­ries B, the biotech sat back down at the ne­go­ti­at­ing ta­ble for more fund­ing. Suf­fice to say, the CNS biotech suc­ceed­ed — and is now set with $100 mil­lion in cash that it se­cured late last year.

The biotech, which orig­i­nal­ly emerged from stealth back in De­cem­ber 2020 with an A and B round worth $113 mil­lion, made its pres­ence known with some ob­jec­tives in mind. Those in­clud­ed tar­gets that would pit Neu­ron23 in the same space as phar­mas like De­nali and Bio­gen in Parkin­son’s dis­ease, and pur­sue a tar­get that Bris­tol My­ers Squibb has run with al­most to the fin­ish line.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.